These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21677361)

  • 1. Heat shock proteins and cancer therapy: the trail grows hotter!
    Subjeck JR; Repasky EA
    Oncotarget; 2011 Jun; 2(6):433-4. PubMed ID: 21677361
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
    Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
    Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovation in myeloma treatments PARP excellence!
    Fonseca R
    Blood; 2011 Dec; 118(24):6234-5. PubMed ID: 22161848
    [No Abstract]   [Full Text] [Related]  

  • 4. Proteotoxic stress targeted therapy (PSTT).
    Sherman MY
    Oncotarget; 2011 May; 2(5):356-7. PubMed ID: 21636878
    [No Abstract]   [Full Text] [Related]  

  • 5. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
    Colland F
    IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 8. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D; Xie Y
    Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Terpos E
    Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
    Sha Z; Goldberg AL
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
    Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen LB; Munshi N; Saxena S; Anderson KC
    Apoptosis; 2004 Mar; 9(2):149-55. PubMed ID: 15004512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
    Stuhler G; Nekova TS
    Blood; 2014 Jul; 124(4):657-8. PubMed ID: 25061173
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
    Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
    Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
    Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
    Terpos E
    Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib influences the expression of malignant plasma cells membrane antigens.
    Tagoug I; Plesa A; Dumontet C
    Eur J Pharmacol; 2013 Apr; 706(1-3):11-6. PubMed ID: 23458070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
    Li JX; Fei XM; Lu H; Hu HJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1204-8. PubMed ID: 22040972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.